An interventional study of Vitamin D tablets and Ispaghula husk in Stress Urinary Incontinence, sponsored by Shalamar Institute of Health Sciences. Completed at 1 site in Pakistan. Open to female participants aged 40 Years to 49 Years. Per ClinicalTrials.gov, last updated 2024-11-14.
Sponsored by Shalamar Institute of Health Sciences · Not applicable, Interventional, and Other
The rationale for conducting the study is based on the fact that stress urinary incontinenc is a prevalent condition among middle age or older women and Vitamin D deficiency may have clinical effects on the pelvic floor muscles and bladder function. Therefore, the study aims to explore the potential link between vitamin D levels and SUI in women in our local population.
The aging process is often associated with a gradual decline in muscle strength, including the weakening of pelvic floor muscles which are largely responsible for pelvic organ support and urinary retention. Weakness of these muscles is linked with urinary incontinence, the most frequently reported symptom of pelvic floor disorders. The most common type of urinary incontinence is stress urinary incontinence (SUI), which affects about 50% of women with increase in incidence with advancing age. The prevalence of stress urinary incontinence is approximately 23.58% in Pakistani middle aged women aged 40-50.
SUI occurs during times of elevated intraabdominal pressure (e.g., sneezing, coughing, and exercise). The levator muscles are responsible for supporting pelvic organs and maintaining the closure of the urethra. Strengthening the pelvic floor muscles through exercise and training is recommended as an effective treatment for SUI. The smooth and skeletal muscles throughout the body have vitamin D receptors. The pelvic floor muscles also express Vitamin D receptors, therefore Vitamin D insufficiency has shown asignificant association with pelvic floor dysfunction. Pelvic floor dysfunction includes symptoms of fecal incontinence, urinary incontinence and pelvic organ prolapse.
This study was conducted to see the association of vitamin D supplementation with improvement in stress incontinence symptoms.
Participants will be explained that their blood will be drawn twice in the study and they need to fill questionnaires with the help of principal investigator. They will be requested to sign a consent form and they will be assured that they can withdraw from the study at any time. SUI will be assessed by completing the standard ICIQ-SF (Incontinence Questionnaire - Urinary Incontinence Short) questionnaire at baseline and Serum concentrations of 25-hydroxy vitamin D will be tested by the ELISA immunoassay as per the protocol of the manufacturer.
The pateints will be divided into two groups by randomization. Group A ( intervention group) and group B (placebo group).All the patients in both groups will be advised pelvic floor exercises which is the standard first line management for stress urinary incontinence. Each study participant will be requested for 3ml of venous blood to determine their vitamin D3 levels. The treatment group will be asked to take vitamin D3 (cholecalciferol)(50,000IU) tablets, once a week, for 8 weeks and control group will be taking placebo ( isphagol husk capsules) weekly for 8 weeks. The research participants will be unaware of the type of preparation being given to them. The principal investigator will be aware of the preparation being given (single blind study).
A telephone check will be done on weekly basis to ensure intake of medication. After 8 weeks vitamin D3 levels will be checked again and standard ICIQ-SF will be assessed at month 1, month 2, and month 3. We expect participants will be enrolled in 2 months. The baseline sample will be analysed in one batch and post intervention sample will be analysed in second batch to minimize bias. Blood will be drawn by the trained phelbotimist under aseptic conditions, The samples will be stored at -80 degree centigrade in two aliquots. One will be used for measuring vitamin D and other will be for emergency purpose if required. If not used it will be discarded as per policy of Shalamar hospital. All the tests will be done in batches using ELISA-kit measuring 25 hydroxy vitamin D as per protocol of the manufacturer. The results will be entered into patient file and research reports provided by research department. Data will be recorded in the electronic system and reports will be given to the participants on their subsequent visits or will be posted to them via whattsapp by the principal investigator.
In case of any adverse drug reaction the patient will report to the principal investigator by telephonic contact and will be managed in emergency of Shalamar Hospital. Expenses for management in emergency will be given by principal investigator. Any adverse event will be reported to the IRB committee by the principal investigator.
Scoring of the stress urinary incontinence will be done based on the questions. The score ranges between 0 to 21. 1-5 (mild), 6-12 (moderate), 13-18 (severe), 19-21 (very severe). Assessment of the improvement of symptoms will be according to the change in severity(mild, moderate, severe or very severe). If the severity decreases as explained in the proforma the treatment will be considered effective The payment of laboratory tests and supplements will be given by research grant from Shalamar medical and dental college Data will be analyzed using the Statistical Package of Social Sciences SPSS version 25.0. Quantitative variables like age, number of deliveries, weight (kg), height (cm). BMI (kg/m2), serum levels of vitamin D (ng/ml) and standard ICIQ-SF score will be presented as Mean+/-SD. Qualitative variables like the impact of the severity of urinary incontinence on life as frequency and percentages. Data will be stratified for weight and number of deliveries. Chi-square test will be used for analyzing urinary incontinence between the two groups. Paired T test will be used to compare the severity of urinary incontinence and quality of life before and after intervention. A p-value of \<0.05 will be considered statistically significant.
1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.
This study's enrollment of 86 is above the median of 66 across 1,011 interventional studies indexed under Urinary Incontinence.
Browse Urinary Incontinence studies →Shalamar Institute of Health Sciences is the lead sponsor of 17 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion Criteria
Exclusion Criteria:
Using hormonal medications (estrogen supplementation)
Group A participants received vitamin D supplements orally for 8 weeks along with pelvic floor exercises
Dietary Supplement: Vitamin D tablets
Group B participants received ispaghula husk tablets for 8 weeks along with pelvic floor exercises
Other: Ispaghula husk
Vitamin D supplements is thought to reduce the severity of urinary incontinence.Vitamin D supplements were given to Group A
Ispaghula husk tablets were given to Group B participants
to see the effect of vitamin supplementation on severity of urinary incontinence
Scoring of the stress urinary incontinence was done based on the International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form Questionnaire. Severity of SUI was based on these scores, 1-5 (mild), 6-12 (moderate), 13-18 (severe), 19-21 (very severe).
Time frame: 0,4,8 and 12 weeks of treatment
Impact on qulaity of life
The ICIQ-SF questionnaire(International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form) included six questions that examined the SUI condition over the past 4 weeks. Items 1 and 2 referred to demographic variables, while item 3 for urinary incontinence frequency. Item 4 measured leakage volume and item 5 evaluated impact on quality of life. Scoring of the stress urinary incontinence was done based on the Questionnaire.
Time frame: 0,4,8 and 12 weeks of treatment
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shalamar Institute of Health Sciences